Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China | Zendy

Xiaofeng Liang | Zendy; Li Li | Zendy; Dawei Liu | Zendy; Keli Li | Zendy; Wendi Wu | Zendy; BaoPing Zhu | Zendy; Huaqing Wang | Zendy; Huiming Luo | Zendy; Lingsheng Cao | Zendy; Jingshan Zheng | Zendy; Dapeng Yin | Zendy; Lei Cao | Zendy; Bingbing Wu | Zendy; Honghong Bao | Zendy; Disha Xu | Zendy; Weizhong Yang | Zendy; Yu Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China

Author(s) -

Xiaofeng Liang,

Li Li,

Dawei Liu,

Keli Li,

Wendi Wu,

BaoPing Zhu,

Huaqing Wang,

Huiming Luo,

Lingsheng Cao,

Jingshan Zheng,

Dapeng Yin,

Lei Cao,

Bingbing Wu,

Honghong Bao,

Disha Xu,

Weizhong Yang,

Yu Wang

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1008553

Subject(s) - medicine , postmarketing surveillance , pandemic , vaccination , china , virology , live attenuated influenza vaccine , h1n1 influenza , environmental health , human mortality from h5n1 , influenza vaccine , influenza a virus , covid-19 , virus , adverse effect , political science , law , disease , infectious disease (medical specialty)

On September 21, 2009, China began administering vaccines, obtained from 10 different manufacturers, against 2009 pandemic influenza A (H1N1) virus infection in priority populations. We aimed to assess the safety of this vaccination program.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research